Drug Information

Drug General Information
Drug ID
D0Z7FK
Former ID
DNCL002257
Drug Name
XMT-1001
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [521999]
Company
Mersana Therapeutics
Target and Pathway
Target(s) Toposisomerase-1 Target Info Inhibitor [531833]
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway DNA replication
Pathway Interaction Database Caspase Cascade in Apoptosis
WikiPathways Integrated Pancreatic Cancer Pathway
References
Ref 521999ClinicalTrials.gov (NCT00455052) A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 531833Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin Cancer Res. 2012 May 1;18(9):2591-602.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.